New immune cell therapy for hard-to-treat blood cancers

Plain-English translation of NCT07321301 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing CAR1920 mRNA CAR-T cell therapy, a treatment that uses your own immune cells and reprograms them to recognize and destroy cancer cells. The medication is delivered using special lipid particles and is designed to target two markers found on B-cell cancers (CD19 and CD20), which makes it harder for cancer cells to escape the immune attack.

Many patients with advanced B-cell lymphomas and leukemias stop responding to standard chemotherapy and other treatments. By targeting two cancer markers instead of one, this medication aims to be more effective and prevent cancers from coming back by reducing the chance that cancer cells can hide from the immune system.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsed or refractory B-cell lymphoma or leukemia that did not respond to or came back after standard treatments
you are between 18 and 85 years old
you have adequate liver, kidney, heart, and lung function as measured by blood tests and imaging
you have received prior treatment with anti-CD20 monoclonal antibody and chemotherapy
you have a life expectancy of at least 14 days from when you sign consent
you are willing to comply with scheduled visits, blood tests, and imaging exams

You likely don't qualify if…

you have severely low blood counts (hemoglobin below 60 g/L, neutrophils below 1,000/μl, or platelets below 45,000/μl) that cannot be corrected
you have significant liver disease with bilirubin higher than 1.5 times the normal limit
you have severely impaired heart function with ejection fraction below 50%
you have severely impaired kidney function with creatinine clearance below 60 mL/min

What participation looks like

As a participant, you would receive the reprogrammed immune cell treatment, likely through infusion visits at the research center. You would have regular follow-up appointments involving blood tests and imaging scans to monitor how well the treatment is working and to watch for any side effects. The study is enrolling about 10 patients total and is currently recruiting, so the exact schedule would be discussed with the research team.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Chinese PLA General Hospital, Beijing, Beijing Municipality